| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2025 | Dec, 2025 |
| Sales | 0 | 5,000 | 0 | 0 | 0 |
| Sales Growth | -100.00% | unch | unch | unch | unch |
| Net Income | -51,870 | -104,870 | -58,790 | 0 | 0 |
| Net Income Growth | +50.54% | -78.38% | unch | unch | unch |
Adlai Nortye Ltd ADR (ANL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Adlai Nortye Ltd. is a clinical-stage biotechnology company. It focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. Adlai Nortye Ltd. is based in SINGAPORE.
Fiscal Year End Date: 12/31